Stifel Nicolaus started coverage on shares of Sionna Therapeutics (NASDAQ:SION – Free Report) in a report issued on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $32.00 price target on the stock.
Separately, Guggenheim assumed coverage on shares of Sionna Therapeutics in a report on Tuesday. They set a “buy” rating and a $45.00 price target for the company.
Get Our Latest Stock Report on Sionna Therapeutics
Sionna Therapeutics Trading Up 2.7 %
Sionna Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Articles
- Five stocks we like better than Sionna Therapeutics
- How to Invest in Small Cap Stocks
- GitLab: Get In While It’s Down—Big Rebound Ahead
- How to buy stock: A step-by-step guide for beginners
- Tesla Stock: Finding a Bottom May Take Time
- Why Are Stock Sectors Important to Successful Investing?
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
